These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 32987729)

  • 21. Safety and efficacy of plerixafor dose escalation for the mobilization of CD34
    Boulad F; Shore T; van Besien K; Minniti C; Barbu-Stevanovic M; Fedus SW; Perna F; Greenberg J; Guarneri D; Nandi V; Mauguen A; Yazdanbakhsh K; Sadelain M; Shi PA
    Haematologica; 2018 May; 103(5):770-777. PubMed ID: 29419425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases γ-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model.
    Rivers A; Vaitkus K; Ruiz MA; Ibanez V; Jagadeeswaran R; Kouznetsova T; DeSimone J; Lavelle D
    Exp Hematol; 2015 Jul; 43(7):546-53.e1-3. PubMed ID: 25931013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
    Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Harvesting, characterization, and culture of CD34+ cells from human bone marrow, peripheral blood, and cord blood.
    Van Epps DE; Bender J; Lee W; Schilling M; Smith A; Smith S; Unverzagt K; Law P; Burgess J
    Blood Cells; 1994; 20(2-3):411-23. PubMed ID: 7538347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for ineffective erythropoiesis in severe sickle cell disease.
    Wu CJ; Krishnamurti L; Kutok JL; Biernacki M; Rogers S; Zhang W; Antin JH; Ritz J
    Blood; 2005 Nov; 106(10):3639-45. PubMed ID: 16091448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversed by blood transfusion.
    Park SY; Matte A; Jung Y; Ryu J; Anand WB; Han EY; Liu M; Carbone C; Melisi D; Nagasawa T; Locascio JJ; Lin CP; Silberstein LE; De Franceschi L
    Blood; 2020 Jun; 135(23):2071-2084. PubMed ID: 31990287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isolation of primitive human bone marrow hematopoietic progenitor cells using Hoechst 33342 and Rhodamine 123.
    Leemhuis T; Yoder MC; Grigsby S; Agüero B; Eder P; Srour EF
    Exp Hematol; 1996 Aug; 24(10):1215-24. PubMed ID: 8765497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severity of Brazilian sickle cell disease patients: severity scores and feasibility of the Bayesian network model use.
    Belini Junior E; Silva DG; Torres Lde S; Okumura JV; Lobo CL; Bonini-Domingos CR
    Blood Cells Mol Dis; 2015 Apr; 54(4):321-7. PubMed ID: 25842370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea.
    Conran N; Fattori A; Saad ST; Costa FF
    Am J Hematol; 2004 Aug; 76(4):343-7. PubMed ID: 15282666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.
    Schneider JG; Crown JP; Wasserheit C; Kritz A; Wong G; Reich L; Norton L; Moore MA
    Bone Marrow Transplant; 1994 Dec; 14(6):877-84. PubMed ID: 7536069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral blood.
    Murray L; Chen B; Galy A; Chen S; Tushinski R; Uchida N; Negrin R; Tricot G; Jagannath S; Vesole D
    Blood; 1995 Jan; 85(2):368-78. PubMed ID: 7529060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous measurement of human hematopoietic stem and progenitor cells in blood using multicolor flow cytometry.
    Cimato TR; Furlage RL; Conway A; Wallace PK
    Cytometry B Clin Cytom; 2016 Sep; 90(5):415-23. PubMed ID: 26663713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function.
    Jing D; Oelschlaegel U; Ordemann R; Hölig K; Ehninger G; Reichmann H; Ziemssen T; Bornhäuser M
    Bone Marrow Transplant; 2010 Oct; 45(10):1489-96. PubMed ID: 20098455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy.
    Fruehauf S; Haas R; Conradt C; Murea S; Witt B; Möhle R; Hunstein W
    Blood; 1995 May; 85(9):2619-26. PubMed ID: 7537123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deficiency of CD34+ c-kit+ and CD34+38- hematopoietic precursors in aplastic anemia after immunosuppressive treatment.
    Manz CY; Nissen C; Wodnar-Filipowicz A
    Am J Hematol; 1996 Aug; 52(4):264-74. PubMed ID: 8701944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease.
    Ware RE; Zimmerman SA; Schultz WH
    Blood; 1999 Nov; 94(9):3022-6. PubMed ID: 10556185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.
    Adly AA; Ismail EA; Andrawes NG; Mahmoud MM; Eladawy R
    Cytokine; 2016 Mar; 79():52-8. PubMed ID: 26765484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
    Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
    Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34(+), CD34(+)38(-), and week-6 CAFC assays predict poor engraftment.
    Robinson SN; Freedman AS; Neuberg DS; Nadler LM; Mauch PM
    Exp Hematol; 2000 Dec; 28(12):1325-33. PubMed ID: 11146154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.